Skip to main content
Equibles
CABA logo

CABA · Cabaletta Bio, Inc.

Track CABA — free

Use CABA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CABA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.13 -0.06 (-1.88%) At close · Aug 21
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have identified conditions that raise substantial doubt about our ability to continue as a going concern. If we are unable to secure additional funding beyond our current cash position that enables our operations into mid-2027, we may be forced to delay, reduce or discontinue our product development programs efforts or other operations. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$530.68M
Shares
169.55M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.13 Open$3.20 Day$3.09–3.34 52W close$1.45–4.15 Avg vol 30d3.6M Short int40.8M · 24.1% float · 18.5d Short vol40% Last earningsNov 14, 2024 DataJan 2020–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +9%
above
Price vs 50-day avg +9%
above
RSI (14) 63
neutral
MACD trend Positive
52-week position 62%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +16%
trailing
6-month return −5%
trailing
YTD return +43%
this year
Relative strength −17%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+27% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
24.05% of float · ▼ -0.6% MoM · 18.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
142 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Strong
EPS growth +10%
Y/Y
Free cash flow $-132.3M
Balance sheet $83.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 99%
annualized · 1-yr
Max drawdown −43%
past year
ATR 6.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+9% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
63 Neutral
MACD trend
Positive Bullish
52-week position
62% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+27% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
24.05% of float · ▼ -0.6% MoM · 18.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
142 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $3 · 62% Range high $4
vs 200-day avg +9% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CABA
Cabaletta Bio, Inc.
this stock
$530.68M +42.9% — — 24.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.66B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
142
% held
95.9%
Net QoQ
+75.6M sh
Top holder
JENNISON ASSOCIATES LLC
Held Float
View
Held by Funds
Fund positions
62
View
Short & Settlement
Short Interest Falling
Shares short
40.8M
Days to cover
18.5d
Change
-232.8K sh
View
Short Volume
Short vol %
40%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
125
Value
$340
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
40.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-167.9M
EPS diluted
$-2.10
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
15
View
Proposed Sales
Value
$592.7K
Shares
33.0K
Filed
Nov 20, 2023
View
Earnings & Events
Earnings Calls
Last call
Jun 8, 2026
View

Performance

5D 20D 120D MTD YTD
CABA +13.8% +16.4% -5.2% +16.8% +42.9%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +15.2% +12.7% -16.7% +14.3% +30.6%
Key facts CIK 1759138 CUSIP 12674W109 13F (30d) 144 filings 139 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)